# A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

Source: https://onco.cc/trials/nct05991583/  
OnCo record `nct05991583` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IBB0979 in advanced solid tumours, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.

## Summary

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05991583 by SUNHO（China）BioPharmaceutical CO., Ltd., with 25 participants planned, started 2023-07-03 and due to reach its primary completion in 2025-11-30. Interventions recorded: IBB0979.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05991583
- Phase: 1/2
- Setting: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBB0979 in Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT05991583: https://clinicaltrials.gov/study/NCT05991583

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05991583.json